News | Focused Ultrasound Therapy | January 08, 2021

Focused Ultrasound Shows Promise for Parkinson's Disease

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s disease symptoms that are much more severe on one side of the body, new research suggests.

More testing is needed, but the approach, which uses a technology called focused ultrasound, could offer a new option for patients whose symptoms are poorly controlled by medications and those who cannot or do not wish to undergo traditional brain surgery.

“This small brain region, the subthalamic nucleus, had a very strong and potent effect on Parkinsonian symptoms when we targeted it with precise, focused ultrasound energy,” said researcher Jeff Elias, M.D., a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. “The key for the ultimate adoption of this new procedure will be further refinements of the technology to ensure reliability and safety.”

About Focused Ultrasound

Focused ultrasound offers a minimally invasive alternative to traditional surgery approaches. The technology focuses sound waves inside the body, much like a magnifying glass focuses light. This allows doctors to interrupt faulty brain circuits or destroy unwanted tissue. Magnetic-resonance imaging (MRI) allows doctors to monitor the procedure in real time – and to make adjustments as needed to obtain the best patient outcomes.

To determine if the technology could benefit patients with “asymmetrical” Parkinson’s symptoms, Elias and Binit Shah, M.D., from UVA’s Department of Neurology, collaborated with Spain’s Centro Intregral de Neurociencias to evaluate the approach in 40 volunteers in a randomized, double-blinded study. Twenty-seven study participants received treatment with focused ultrasound, while 13 others received a simulated treatment, so that the researchers could compare the results between the real procedure and the placebo. The average age of study participants was 57.

The volunteers’ symptoms before and after the procedure were assessed on a scale of 1-44. Those who received the focused ultrasound procedure saw an improvement of 10 points, while those who received the sham treatment saw a difference of less than two points.

The study also looked at the safety of the procedure. Side effects included unwanted movements, muscle weakness, speech disturbances and difficulty walking. In most cases, these were temporary, but some effects persisted in six patients a year later.

The results warrant additional studies in larger numbers of volunteers conducted over longer periods of time, the researchers conclude.

“Parkinson’s disease affects patients in more ways than just tremor,” Shah said. “The current FDA approval for focused ultrasound in Parkinson’s disease treats only tremor. Targeting this new area allows us to improve tremor but also get more overall benefit for our patients than we previously were able to achieve.”

About UVA’s Focused Ultrasound Research

UVA has been at the leading edge of research into the technology’s potential to treat disease. For example, the federal Food and Drug Administration approved focused ultrasound for the treatment of essential tremor, a common movement disorder, based on Elias’ pioneering research. His work also paved the way for the FDA to authorize the technology to treat tremors caused by Parkinson’s disease.

Other researchers at UVA are investigating the technology’s potential to treat a wide variety of conditions, including epilepsy and breast cancer.

Findings Published

Elias and his colleagues have published their latest findings in the prestigious New England Journal of Medicine. The research team consisted of Raúl Martínez-Fernández, Jorge U. Máñez-Miró, Rafael Rodríguez-Rojas, Marta del Álamo, Binit B. Shah, Frida Hernández-Fernández, Jose A. Pineda-Pardo, Mariana H.G. Monje, Beatriz Fernández-Rodríguez, Scott A. Sperling, David Mata-Marín, Pasqualina Guida, Fernando Alonso-Frech, Ignacio Obeso, Carmen Gasca-Salas, Lydia Vela-Desojo, Elias and Jose A. Obeso.

The research was supported by InSightec, the manufacturer of the focused ultrasound technology; Charlottesville’s Focused Ultrasound Foundation, a longtime supporter of UVA’s focused ultrasound research; Fundación MAPFRE in Madrid; Fundación Hospitales de Madrid; and a University of Virginia Center of Excellence grant. Elias disclosed that his department at UVA has received research funding from InSightec, but the company had no role in the study design or analysis. A full list of author disclosures is included in the paper in the New England Journal of Medicine.

For more information: www.uvahealth.com

Related Content

The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

Getty Images

News | Coronavirus (COVID-19) | January 08, 2021
January 8, 2021 — The U.S.
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...
In this roundtable discussion hosted by ITN Editorial Director Melinda Taschetta-Millane, three medical experts will discuss the impact COVID-19 had on the industry in 2020, as well as projections for the industry in 2021.
Webinar | Coronavirus (COVID-19) | January 06, 2021
2020 was an unprecedented year, as the world grappled with a...
Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. #AI #AIhealthcare #AIecho

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

News | Artificial Intelligence | January 06, 2021
January 6, 2021 — The U.S.
OptumInsight and Change Healthcare combine to advance a more modern, information and technology-enabled healthcare platform

Getty Images

News | Information Technology | January 06, 2021
January 6, 2020 — Optum, a diversified health services company and
Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
News | Breast Imaging | January 04, 2021
January 4, 2021 — Smart Breast Corporation (SmartBreast), a privately held company focused on...
#coronavirus #COVID19 #pandemic

Getty Images

News | Radiology Imaging | January 01, 2021
The Imaging Technology News (ITN) team wishes you a Happy and Healthy New Year!
After “COVID-19,” the term that most people will remember best from 2020 is likely to be “social distancing.” While it most commonly applied to social gatherings with family and friends, it has impacted the way many receive medical care. Historically, the United States has been relatively slow to broadly adopt telemedicine, largely emphasizing in-person visits.

Getty Images

News | Teleradiology | December 31, 2020
December 31, 2020 — After “COVID-19,” the term t
Now, researchers using magnetic resonance imaging (MRI) have found potential brain biomarkers of PTSD in people with traumatic brain injury (TBI).
News | Magnetic Resonance Imaging (MRI) | December 31, 2020
December 31, 2020 — Posttraumatic stress disorder (...